IP Library Granted Patent US 12,635,916
Granted Patent B2
US 12,635,916 · App. 18/588,645 · Granted May 26, 2026

Method and/or system for determining blood glucose reference sample times

Inventors: Rebecca K. Gottlieb (Culver City, CA); Meena Ramachandran (San Francisco, CA)
Assignee: Medtronic MiniMed, Inc.
A61B5/14532A61B5/14503A61B5/4839A61B5/6849A61B5/7221A61B5/742A61M5/14244A61M5/1723A61M2005/14208A61M2205/18A61M2205/50A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,635,916
App. No.
18/588,645
Granted
May 26, 2026
Kind
B2
Abstract

Techniques disclose herein relate to determining glucose reference sample times. The techniques may involve determining a first glucose reference sample measurement for a patient. The techniques may further involve determining timing information for obtaining a second glucose reference sample measurement based at least in part on readings from a continuous glucose sensor.

Claims (31)

1 . A method comprising:

determining a first glucose reference sample measurement for a patient according to a schedule;

determining timing information for obtaining a second glucose reference sample measurement based at least in part on a comparison of readings from a continuous glucose sensor to a first threshold and a difference between the first glucose reference sample measurement and an upper bound of a target range glucose level being less than a second threshold, wherein the first glucose reference sample has a value greater than the upper bound, wherein determining the timing information comprises determining a change to the schedule for obtaining glucose reference sample measurements for the patient; and

presenting an alert indicating the change to the schedule.

2 . The method of claim 1 , wherein the first glucose reference sample measurement and the second glucose reference sample measurement are metered glucose sample measurements.

3 . The method of claim 1 , wherein determining the timing information is based on a reliability of the continuous glucose sensor.

4 . The method of claim 1 , wherein determining the timing information comprises determining an earlier than scheduled time for obtaining the second glucose reference sample measurement.

5 . The method of claim 1 , further comprising causing at least one of: displaying a time the second glucose reference sample measurement is to be obtained, or causing an alarm to be presented.

6 . The method of claim 1 , wherein the comparison comprises comparing a glucose level of the patient and a predetermined target range, and wherein the timing information for obtaining the second glucose reference sample measurement is based on the comparison.

7 . The method of claim 6 , further comprising determining a duration of time the glucose level of the patient has been within the predetermined target range to determine the timing information.

8 . The method of claim 6 , wherein the predetermined target range is defined based on a target glucose level that varies over time.

9 . The method of claim 6 , wherein the glucose level is one of: an observed glucose level based on the first glucose reference sample measurement, or a predicted glucose level of the patient.

10 . The method of claim 1 , wherein determining the timing information for obtaining the second glucose reference sample measurement comprises determining a duration of time to delay obtaining the second glucose reference sample measurement from a scheduled time.

11 . The method of claim 1 , wherein determining the timing information comprises determining a trend of glucose levels of the patient based on the readings from the continuous glucose sensor.

12 . The method of claim 1 , wherein determining the timing information comprises determining a variability of glucose levels of the patient over a previous time period based on the readings from the continuous glucose sensor.

13 . A system comprising:

one or more processors; and

one or more non-transitory processor-readable media storing instructions which, when executed by one or more processors, cause performance of:

determining a first glucose reference sample measurement for a patient according to a schedule;

determining timing information for obtaining a second glucose reference sample measurement based at least in part on a comparison of readings from a continuous glucose sensor to a first threshold and a difference between the first glucose reference sample measurement and an upper bound of a target range glucose level being less than a second threshold, wherein the first glucose reference sample has a value greater than the upper bound, wherein determining the timing information comprises determining a change to the schedule for obtaining glucose reference sample measurements for the patient; and

presenting an alert indicating the change to the schedule.

14 . The system of claim 13 , wherein the first glucose reference sample measurement and the second glucose reference sample measurement are metered glucose sample measurements.

15 . The system of claim 13 , wherein determining the timing information is based on a reliability of the continuous glucose sensor.

16 . The system of claim 13 , wherein the one or more processors further cause performance of determining an earlier than scheduled time for obtaining the second glucose reference sample measurement.

17 . The system of claim 13 , wherein the one or more processors further cause performance of at least one of: displaying a time the second glucose reference sample measurement is to be obtained, or presenting an alarm.

18 . A method comprising:

obtaining a first glucose reference sample measurement for a patient according to a schedule;

determining timing information for obtaining a subsequent glucose reference sample measurement after the first glucose reference sample measurement to be used to calibrate a continuous glucose sensor based at least in part on a reliability of readings from the continuous glucose sensor and based on a comparison of readings from a continuous glucose sensor to a first threshold and further based on a difference between the first glucose reference sample measurement and an upper bound of a target range glucose level being less than a second threshold, wherein the first glucose reference sample has a value greater than the upper bound, wherein determining the timing information comprises determining a change to the schedule for obtaining a second glucose reference sample measurement for the patient; and

presenting an alert indicating the change to the schedule.

19 . The method of claim 18 , wherein determining the timing information comprises determining an earlier than scheduled time for obtaining the second glucose reference sample measurement.

20 . The method of claim 18 , further comprising causing at least one of: displaying a time the second glucose reference sample measurement is to be obtained, or causing an alarm to be presented.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2024
From: GOTTLIEB, REBECCA K.; RAMACHANDRAN, MEENA
To: MEDTRONIC MINIMED, INC.
Reel/Frame 066580/0606 →
Continuity (7)
Continuation 17552264 · Dec 15, 2021
Continuation 16559416 · Sep 3, 2019
Continuation 15268063 · Sep 16, 2016
Continuation 13171244 · Jun 28, 2011
Provisional Application 61407888 · Oct 28, 2010
Provisional Application 61361876 · Jul 6, 2010
Related Publication 20240197212A1 · Jun 20, 2024
References Cited (98)
US 5126952A · Kildal-Brandt et al. · 1992 [cited by applicant]
US 5822715A · Worthington et al. · 1998 [cited by applicant]
US 6280381B1 · Malin et al. · 2001 [cited by applicant]
US 7695677B2 · Werner et al. · 2010 [cited by applicant]
US 7833157B2 · Gottlieb et al. · 2010 [cited by applicant]
US 8657746B2 · Roy · 2014 [cited by applicant]
US 8919180B2 · Gottlieb et al. · 2014 [cited by applicant]
US 9033878B2 · Liang et al. · 2015 [cited by applicant]
US 9402569B2 · Liang et al. · 2016 [cited by applicant]
US 10433774B2 · Gottlieb et al. · 2019 [cited by applicant]
US 11224362B2 · Gottlieb et al. · 2022 [cited by applicant]
US 11957459B2 · Gottlieb et al. · 2024 [cited by applicant]
US 20020035318A1 · Mannheimer et al. · 2002 [cited by applicant]
US 20020106709A1 · Potts et al. · 2002 [cited by applicant]
US 20020161288A1 · Shin et al. · 2002 [cited by applicant]
US 20030050546A1 · Desai et al. · 2003 [cited by applicant]
US 20030130616A1 · Steil et al. · 2003 [cited by applicant]
US 20050038332A1 · Saidara · 2005 [cited by examiner]
US 20060020190A1 · Kamath et al. · 2006 [cited by applicant]
US 20070016381A1 · Kamath et al. · 2007 [cited by applicant]
US 20080161664A1 · Mastrototaro et al. · 2008 [cited by applicant]
US 20080249386A1 · Besterman et al. · 2008 [cited by applicant]
US 20080288180A1 · Hayter et al. · 2008 [cited by applicant]
US 20080300572A1 · Rankers et al. · 2008 [cited by applicant]
US 20090036747A1 · Hayter et al. · 2009 [cited by applicant]
US 20090054753A1 · Robinson et al. · 2009 [cited by applicant]
US 20090055149A1 · Hayter et al. · 2009 [cited by applicant]
US 20090156924A1 · Shariati · 2009 [cited by examiner]
US 20090192751A1 · Kamath · 2009 [cited by examiner]
US 20100045465A1 · Brauker et al. · 2010 [cited by applicant]
US 20100081909A1 · Budiman et al. · 2010 [cited by applicant]
US 20100162786A1 · Keenan et al. · 2010 [cited by applicant]
US 20100168538A1 · Keenan et al. · 2010 [cited by applicant]
US 20100234710A1 · Budiman et al. · 2010 [cited by applicant]
US 20110184268A1 · Taub · 2011 [cited by applicant]
US 20110184269A1 · Sauter-Starace et al. · 2011 [cited by applicant]
US 20110313390A1 · Roy et al. · 2011 [cited by applicant]
US 20110320166A1 · Luo et al. · 2011 [cited by applicant]
US 20120006100A1 · Gottlieb et al. · 2012 [cited by applicant]
US 20120108932A1 · Roy · 2012 [cited by applicant]
US 20130144254A1 · Amirouche et al. · 2013 [cited by applicant]
US 20160175520A1 · Palerm et al. · 2016 [cited by applicant]
US 20170065212A1 · Gottlieb et al. · 2017 [cited by applicant]
US 20190388014A1 · Gottlieb et al. · 2019 [cited by applicant]
US 20220104734A1 · Gottlieb et al. · 2022 [cited by applicant]
CN 102970927B · 2016 [cited by applicant]
CN 107095681A · 2017 [cited by applicant]
CN 107095681B · 2020 [cited by applicant]
WO 0074753A1 · 2000 [cited by applicant]
WO 2006050032A2 · 2006 [cited by applicant]
WO 2008151452A1 · 2008 [cited by applicant]
WO 2012006208A2 · 2012 [cited by applicant]
Bagshaw, S.M., et al., “The impact of early hypoglycemia and blood glucose variability on outcome in critical illness”, Critical care medicine, 2009, vol. 13, No. 3, pp. 91. [cited by applicant]
CN Application. No. 201180033381.1 115.P019PCTCN: First Office Action, Mar. 26, 2014, 12 pages. [cited by applicant]
CN Application. No. 201180033381.1 115.P019PCTCN: Second Office Action Oct. 21, 2014, 12 pages. [cited by applicant]
CN Office Action dated May 6, 2015, 16 pages, in application No. CN201180033381.8. [cited by applicant]
CN Office Action dated on Nov. 3, 2015, 9 pages in application No. CN201180033381.8. [cited by applicant]
Communication pursuant to Article 94(3) EPC dated on Nov. 5, 2013, 4 pages in EP11731222.3. [cited by applicant]
Communication pursuant to Rule 69 EPC dated on Oct. 4, 2016, 2 pages, in EP16153071.2. [cited by applicant]
Communication under Rule 71(3) EPC, Sep. 28, 2018, 53 pages in EP16153071.2. [cited by applicant]
EP Application. no 11731222.3-1660/115.P019PCTEP: First Office action, mailed Nov. 5, 2013, 5 pages. [cited by applicant]
EP Application. no. 11731222.3-1660/115.P019PCTEP: Second office action, mailed Aug. 4, 2014, 4 pages. [cited by applicant]
EP Application No. 16153071.2-1666 I 3037037: Extended Search Report, Aug. 26, 2016, 10 pages. [cited by applicant]
EP Extended Search report dated Jul. 30, 2019, in Application No. 19150324. [cited by applicant]
EP Extened Search report dated Aug. 26, 2016, in Application No. 16153071. [cited by applicant]
EP Office Action dated on Sep. 25, 2015, 4 pages in EP11731222.3. [cited by applicant]
EP Partial Search report dated May 6, 2016, in Application No. 16153071. [cited by applicant]
EPO, European Office Action, dated Jan. 4, 2015, European Patent ApplicationNo. 11731222.3-1660, 4 pages. [cited by applicant]
EPO Office Action dated on Apr. 1, 2015, 4 pages in EP11731222.3. [cited by applicant]
EPO Office Action dated on Aug. 4, 2014, 4 pages in PCT/US2011/042560. [cited by applicant]
EPO Office Action dated on Nov. 5, 2013, 5 pages in PCT/US2011/042560. [cited by applicant]
Examiner's Report dated on Apr. 10, 2017, 4 pages in CA2802271. [cited by applicant]
Examiner's Report dated on Feb. 28, 2018, 4 pages in CA2802271. [cited by applicant]
Goldberg, P.A., et al., “Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients”, Diabetes Spectrum, 2005, vol. 18(3), pp. 188-191. [cited by applicant]
Goldberg, P.A., et al., “Implementation of a Safe and Effective Insulin Infusion Protocol in a Medical Intensive Care Unit”, Diabetes Car, 2004, vol. 27(2), pp. 461-467. [cited by applicant]
Hermandides, J., et al., “Glucose variability is associated with intensive care unit mortality”, Critical care medicine, 2010, vol. 38, pp. 838-842. [cited by applicant]
International Preliminary Report on Patentability dated Jan. 17, 2013 in Application No. PCT/US2011/042560. [cited by applicant]
International Search Report and Written Opinion dated Mar. 9, 2012 in PCT Application No. PCT/US2011/042560. [cited by applicant]
Krinsley, U.S., et al., “Glycemic variability: A strong independent predictor of mortality in critically ill patients”, Critical care medicine, 2008, vol. 36, No. 11, pp. 3008-3013. [cited by applicant]
Partial Search Report dated on May 6, 2016, 7 pages in EP16153071.2. [cited by applicant]
Response, filed Jan. 18, 2016, to Office Action dated Nov. 3, 2015, Chinese Patent Application No. 201180033381.8, 9 pages. [cited by applicant]
SIPO, Fifth Office Action, dated May 5, 2016, Chinese Patent Application No. 201180033381.8, 9 pages. [cited by applicant]
SIPO First Office Action dated on Mar. 26, 2013, 12 pages in PCT/CN101065060. [cited by applicant]
SIPO Second Office Action dated on Oct. 21, 2014, 12 pages in PCT/CN101065060. [cited by applicant]
Summons to attend oral proceedings pursuant to Rule 115(1) EPC dated on Apr. 1, 2015, 7 pages in EP11731222.3. [cited by applicant]
U.S. Appl. No. 13/171,244 I: Non-Final Rejection, mailed Nov. 4, 2014, 18 pages. [cited by applicant]
U.S. Final Office Action dated Feb. 21, 2019, in U.S. Appl. No. 15/268,063. [cited by applicant]
U.S. Final office Action dated May 18, 2016 in U.S. Appl. No. 13/171,244. [cited by applicant]
U.S. Final office Action dated May 19, 2015 in U.S. Appl. No. 13/171,244. [cited by applicant]
U.S. Non-Final Office Action dated Jun. 21, 2018, in U.S. Appl. No. 15/268,063. [cited by applicant]
U.S. Non-Final Office Action dated Nov. 4, 2014, in U.S. Appl. No. 13/171,244. [cited by applicant]
U.S. Non-Final Office Action dated Oct. 15, 2015, in U.S. Appl. No. 13/171,244. [cited by applicant]
U.S. Non-Final Office Action dated Sep. 1, 2023, in U.S. Appl. No. 17/552,264. [cited by applicant]
U.S. Notice of Allowance dated May 16, 2019 in U.S. Appl. No. 15/268,063. [cited by applicant]
U.S. Notice of Allowance dated Nov. 29, 2023 in U.S. Appl. No. 17/552,264. [cited by applicant]
U.S. Notice of Allowance dated Sep. 4, 2019 in U.S. Appl. No. 15/268,063. [cited by applicant]
U.S. Notice of Allowance dated Sep. 16, 2021, in U.S. Appl. No. 16/559,416. [cited by applicant]
Van Den Berghe, G., et al., “Intensive Insulin Therapy in Critically Ill Patients” The New England Journal of Medicine, Nov. 8, 2001, vol. 345(19), pp. 1359-1367. [cited by applicant]